Navigation

P18

Poster
Evaluating the potential effect of L-Carnitine on the prevention of atrial fibrillation following coronary artery bypass graft surgery: a Randomized Clinical Trial

F. Dastan (Tehran TR)


Aim: Atrial Fibrillation [AF] is one of the most common complications in patients who undergo coronary artery bypass graft surgery [CABG]. The aim of this study was to evaluate the effect of L-carnitine administration on postoperative AF and acute kidney injury following CABG.

Design & methods: One hundred and thirty four patients undergoing elective CABG, without history of AF or previous L-carnitine treatment, were randomly assigned to an L-carnitine group (3000 mg/day L-carnitine) or a control group. CRP levels, as a biomarker of inflammation, were assessed in all the patients before surgery as baseline levels and 48 hours postoperatively. Neutrophil gelatinase-associated lipocalin (NGAL), as a kidney biomarker, was also measured in the patients before surgery and 2 hours thereafter.

Results: The incidence of AF was 13.4% in our population. L-carnitine significantly reduced the incidence of postoperative AF (7.5% in the L-carnitine group vs. 19.4% in the control group; p value=0.043) and postoperative CRP level (8.79±6.9 in the L-carnitine group vs. 10.83±5.7 in the control group; p value=0.021). Postoperative NGAL concentration demonstrated no significant rise after surgery compared with the preoperative concentration (72.54±20.30 in the L-carnitine group vs. 67.68±22.71 in the placebo group; p value=0.19).

Conclusions: Our study showed that L-carnitine administration before CABG may inhibit and reduce the incidence of post-CABG AF. It seems that a rise in the CRP level, as an inflammation marker, may be associated with the incidence of AF.

    
        Array
(
    [id] => 10
    [abstract_id] => 47
    [session_id] => 1
    [pres_nbr] => P18
    [updated] => 
    [created] => 0000-00-00 00:00:00
    [abstract] => Array
        (
            [id] => 47
            [user_id] => 26
            [contact_id] => 24
            [knr] => 74d626fe
            [titel] => Evaluating the potential effect of L-Carnitine on the prevention of atrial fibrillation following coronary artery bypass graft surgery: a Randomized Clinical Trial

            [text] => 

Aim: Atrial Fibrillation [AF] is one of the most common complications in patients who undergo coronary artery bypass graft surgery [CABG]. The aim of this study was to evaluate the effect of L-carnitine administration on postoperative AF and acute kidney injury following CABG.

Design & methods: One hundred and thirty four patients undergoing elective CABG, without history of AF or previous L-carnitine treatment, were randomly assigned to an L-carnitine group (3000 mg/day L-carnitine) or a control group. CRP levels, as a biomarker of inflammation, were assessed in all the patients before surgery as baseline levels and 48 hours postoperatively. Neutrophil gelatinase-associated lipocalin (NGAL), as a kidney biomarker, was also measured in the patients before surgery and 2 hours thereafter.

Results: The incidence of AF was 13.4% in our population. L-carnitine significantly reduced the incidence of postoperative AF (7.5% in the L-carnitine group vs. 19.4% in the control group; p value=0.043) and postoperative CRP level (8.79±6.9 in the L-carnitine group vs. 10.83±5.7 in the control group; p value=0.021). Postoperative NGAL concentration demonstrated no significant rise after surgery compared with the preoperative concentration (72.54±20.30 in the L-carnitine group vs. 67.68±22.71 in the placebo group; p value=0.19).

Conclusions: Our study showed that L-carnitine administration before CABG may inhibit and reduce the incidence of post-CABG AF. It seems that a rise in the CRP level, as an inflammation marker, may be associated with the incidence of AF.

[pres_form] => [bio_presenting_author] => [german_presentation] => 0 [contact_complete] => 1 [authors_complete] => 1 [abstract_complete] => 1 [images_complete] => 1 [confirmation_complete] => 1 [updated] => [created] => 2019-03-01 18:11:25 [sprache] => en [atherosclerosis_basic] => 0 [atherosclerosis_clinical] => 0 [heartfailure_basic] => 0 [heartfailure_clinical] => 0 [arrhythmia_basic] => 0 [arrhythmia_clinical] => 0 [hypertension_diabetes_dyslipidemia] => 0 [preventive_medicine] => 1 [contact] => stdClass Object ( [id] => 24 [user_id] => 26 [anrede] => 2 [akad_titel] => 5 [vorname] => Farzaneh [name] => Dastan [institution] => Shahid Beheshti University of Medical Sciences [department] => Department of Clinical Pharmacy, School of Pharmacy [adresszeile1] => No. 18, Amir Abadi, velenjak [adresszeile2] => [adresszeile3] => [plz] => 1984614719 [ort] => Tehran [land] => TR [email] => fzh.dastan@gmail.com [telefon] => [lang] => [updated] => [created] => 0000-00-00 00:00:00 ) [authors] => Array ( [0] => stdClass Object ( [id] => 111 [abstract_id] => 47 [vorname] => Farzaneh [name] => Dastan [qualification] => [institution] => Shahid Beheshti University of Medical Sciences [ort] => Tehran [land] => TR [sort] => 1 [is_presenting_author] => yes [updated] => [created] => 0000-00-00 00:00:00 ) ) [files] => Array ( ) [main_author] => stdClass Object ( [id] => 111 [abstract_id] => 47 [vorname] => Farzaneh [name] => Dastan [qualification] => [institution] => Shahid Beheshti University of Medical Sciences [ort] => Tehran [land] => TR [sort] => 1 [is_presenting_author] => yes [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_contact] =>
Farzaneh Dastan
TR-1984614719 Tehran
fzh.dastan@gmail.com ) [session] => stdClass Object ( [id] => 1 [name] => Poster [date] => 2019-05-09 [start] => 00:00:00 [end] => 00:00:00 [abbr] => P [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_authors] => F. Dastan (Tehran TR) [detail_url] => https://www.iscp2019.com/abstracts/presentation/10 )